The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group
Open accessAbstract
PURPOSE: Treatment planning for children with neuroblastoma requires accurate assessment of prognosis. The most recent Children's Oncology Group (COG) risk classification system used tumor stage as defined by the International Neuroblastoma Staging System. Here, we validate a revised classifier using the International Neuroblastoma Risk Group Staging System (INRGSS) and incorporate segmental chromosome aberrations (SCA) as an additional genomic biomarker. METHODS: Newly diagnosed patients enrolled on the COG neuroblastoma biology study ANBL00B1 between 2007 and 2017 with known age, International Neuroblastoma Staging System, and INRGSS stage were identified (N = 4,832). Tumor MYCN status, ploidy, SCA status (1p and 11q), and International Neuroblastoma Pathology Classification histology were determined centrally. Survival analyses were performed for combinations of prognostic factors used in COG risk classification according to the prior version 1, and to validate a revised algorithm (version 2). RESULTS: Most patients with locoregional tumors had excellent outcomes except for those with image-defined risk factors (INRGSS L2) with MYCN amplification (5-year event-free survival and overall survival: 76.3% ± 5.8% and 79.9% ± 5.5%, respectively) or patients age ≥ 18 months with L2 MYCN nonamplified tumors with unfavorable International Neuroblastoma Pathology Classification histology (72.7% ± 5.4% and 82.4% ± 4.6%), which includes the majority of L2 patients with SCA. For patients with stage M (metastatic) and MS (metastatic, special) disease, genomic biomarkers affected risk group assignment for those < 12 months ( MYCN) or 12-18 months ( MYCN, histology, ploidy, and SCA) of age. In a retrospective analysis of patient outcome, the 5-year event-free survival and overall survival using COG version 1 were low-risk: 89.4% ± 1.1% and 97.9% ± 0.5%; intermediate-risk: 86.1% ± 1.3% and 94.9% ± 0.8%; high-risk: 50.8% ± 1.4% and 61.9% ± 1.3%; and using COG version 2 were low-risk: 90.7% ± 1.1% and 97.9% ± 0.5%; intermediate-risk: 85.1% ± 1.4% and 95.8% ± 0.8%; high-risk: 51.2% ± 1.4% and 62.5% ± 1.3%, respectively. CONCLUSION: A revised 2021 COG neuroblastoma risk classifier (version 2) that uses the INRGSS and incorporates SCAs has been adopted to prospectively define COG clinical trial eligibility and treatment assignment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castel, V, Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1466 · Cited by 2,294
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Cohn, S. L., Pearson, A. D. J., London, W. B., Monclair, T., Ambros, P. F., Brodeur, G. M., Faldum, A., Hero, B., Iehara, T., Machin, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6785 · Cited by 1,910
Self-citationAnti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835 · cited 3×
“Patients were designated as low-risk (LR),(24) intermediaterisk (IR),(22,25) or HR using the COG v1 classifier and treated accordingly.(10,13,26,27)”
BackgroundMethodSelf-citationThe International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
Monclair, T., Brodeur, G. M., Ambros, P. F., Brisse, H. J., Cecchetto, G., Holmes, K., Kaneko, M., London, W. B., Matthay, K. K., Nuchtern, J. G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6876 · Cited by 1,150
Self-citationThe International Neuroblastoma Pathology Classification (the Shimada system)
Shimada, H., Ambros, I. M., Dehner, L. P., Hata, J.-I., Joshi, V. V., Roald, B., Stram, D. O., Gerbing, R. B., Lukens, J. N., Matthay, K. K., et al. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990715)86:2<364::aid-cncr21>3.0.co;2-7 · Cited by 1,067
Self-citationAdvances in Risk Classification and Treatment Strategies for Neuroblastoma
Pinto, N. R., Applebaum, M. A., Volchenboum, S. L., Matthay, K. K., London, W. B., Ambros, P. F., Nakagawara, A., Berthold, F., Schleiermacher, G., Park, J. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4648 · Cited by 911
Self-citationTelomerase activation by genomic rearrangements in high-risk neuroblastoma
Peifer, M., Hertwig, F., Roels, F., Dreidax, D., Gartlgruber, M., Menon, R., Krämer, A., Roncaioli, J. L., Sand, F., Heuckmann, J. M., et al. (2015) · Nature · doi:10.1038/nature14980 · Cited by 595
London, W. B., Castleberry, R. P., Matthay, K. K., Look, A. T., Seeger, R. C., Shimada, H., Thorner, P., Brodeur, G., Maris, J. M., Reynolds, C. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.571 · Cited by 589
Self-citationChromosome 1p and 11q Deletions and Outcome in Neuroblastoma
Attiyeh, E. F., London, W. B., Mossé, Y. P., Wang, Q., Winter, C., Khazi, D., McGrady, P. W., Seeger, R. C., Look, A. T., Shimada, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052399 · Cited by 580
Self-citationBrisse, H. J., McCarville, M. B., Granata, C., Krug, K. B., Wootton-Gorges, S. L., Kanegawa, K., Giammarile, F., Schmidt, M., Shulkin, B. L., Matthay, K. K., et al. (2011) · Radiology · doi:10.1148/radiol.11101352 · Cited by 520
Self-citationAmbros, P. F., Ambros, I. M., Brodeur, G. M., Haber, M., Khan, J., Nakagawara, A., Schleiermacher, G., Speleman, F., Spitz, R., London, W. B., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605014 · Cited by 404
Self-citationIrwin, M. S., & Park, J. R. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.015 · Cited by 392
Self-citationPark, J. R., Kreissman, S. G., London, W. B., Naranjo, A., Cohn, S. L., Hogarty, M. D., Tenney, S. C., Haas-Kogan, D., Shaw, P. J., Kraveka, J. M., et al. (2019) · JAMA · doi:10.1001/jama.2019.11642 · Cited by 358
Self-citationLadenstein, R., Pötschger, U., Pearson, A. D. J., Brock, P., Luksch, R., Castel, V., Yaniv, I., Papadakis, V., Laureys, G., Malis, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30070-0 · Cited by 350
Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma
Janoueix-Lerosey, I., Schleiermacher, G., Michels, E., Mosseri, V., Ribeiro, A., Lequin, D., Vermeulen, J., Couturier, J., Peuchmaur, M., Valent, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0630 · Cited by 349
A mechanistic classification of clinical phenotypes in neuroblastoma
Ackermann, S., Cartolano, M., Hero, B., Welte, A., Kahlert, Y., Roderwieser, A., Bartenhagen, C., Walter, E., Gecht, J., Kerschke, L., et al. (2018) · Science · doi:10.1126/science.aat6768 · Cited by 335
Children's Oncology Group's 2013 blueprint for research: Neuroblastoma
Park, J. R., Bagatell, R., London, W. B., Maris, J. M., Cohn, S. L., Mattay, K. M., Hogarty, M., & on behalf of the COG Neuroblastoma Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24433 · Cited by 332
Self-citationKreissman, S. G., Seeger, R. C., Matthay, K. K., London, W. B., Sposto, R., Grupp, S. A., Haas-Kogan, D. A., LaQuaglia, M. P., Yu, A. L., Diller, L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70309-7 · Cited by 304
Self-citationClinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma
Asgharzadeh, S., Salo, J. A., Ji, L., Oberthuer, A., Fischer, M., Berthold, F., Hadjidaniel, M., Liu, C. W.-Y., Metelitsa, L. S., Pique-Regi, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9169 · Cited by 285
Self-citationSchmidt, M. L., Lukens, J. N., Seeger, R. C., Brodeur, G. M., Shimada, H., Gerbing, R. B., Stram, D. O., Perez, C., Haase, G. M., & Matthay, K. K. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1260 · Cited by 241
Self-citationAsgharzadeh, S., Pique-Regi, R., Sposto, R., Wang, H., Yang, Y., Shimada, H., Matthay, K., Buckley, J., Ortega, A., & Seeger, R. C. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj330 · Cited by 237
Self-citationStrother, D. R., London, W. B., Schmidt, M. L., Brodeur, G. M., Shimada, H., Thorner, P., Collins, M. H., Tagge, E., Adkins, S., Reynolds, C. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.9990 · Cited by 234
Self-citationSchleiermacher, G., Mosseri, V, London, W. B., Maris, J. M., Brodeur, G. M., Attiyeh, E., Haber, M., Khan, J., Nakagawara, A., Speleman, F., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.375 · Cited by 192
Self-citationAccumulation of Segmental Alterations Determines Progression in Neuroblastoma
Schleiermacher, G., Janoueix-Lerosey, I., Ribeiro, A., Klijanienko, J., Couturier, J., Pierron, G., Mosseri, V., Valent, A., Auger, N., Plantaz, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7955 · Cited by 168
George, R. E., London, W. B., Cohn, S. L., Maris, J. M., Kretschmar, C. S., Diller, L., Brodeur, G. M., Castleberry, R. P., & Look, A. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.582 · Cited by 150
Self-citationSchmidt, M. L., Lal, A., Seeger, R. C., Maris, J. M., Shimada, H., O’Leary, M., Gerbing, R. B., & Matthay, K. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.183 · Cited by 150
Self-citationPark, J. R., Scott, J. R., Stewart, C. F., London, W. B., Naranjo, A. H., Santana, V. M., Shaw, P. J., Cohn, S. L., & Matthay, K. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3293 · Cited by 142
Self-citationPrognostic Impact of Gene Expression–Based Classification for Neuroblastoma
Oberthuer, A., Hero, B., Berthold, F., Juraeva, D., Faldum, A., Kahlert, Y., Asgharzadeh, S., Seeger, R., Scaruffi, P., Tonini, G. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3367 · Cited by 135
Self-citationTwist, C. J., Schmidt, M. L., Naranjo, A. H., London, W. B., Tenney, S. C., Marachelian, A., Shimada, H., Collins, M. H., Esiashvili, N., Adkins, E. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00919 · Cited by 131
Self-citationTelomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma
Koneru, B., López, G., Farooqi, A. S., Conkrite, K. L., Nguyen, T. H., Macha, S. J., Modi, A., Rokita, J. L., Urias, E., Hindle, A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3068 · Cited by 118
Self-citationDepuydt, P., Boeva, V., Hocking, T. D., Cannoodt, R., Ambros, I. M., Ambros, P. F., Asgharzadeh, S., Attiyeh, E. F., Combaret, V., Defferrari, R., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy022 · Cited by 101
Self-citationSchleiermacher, G., Michon, J. M., Ribeiro, A., Pierron, G., Mosseri, V., Rubie, H., Munzer, C., Bénard, J., Auger, N., Combaret, V., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.472 · Cited by 99
(SFCE), O. B. O. T. S. F. D. C. D. L., Schleiermacher, G., Michon, J. M., Huon, I., d’Enghien, C. D., Klijanienko, J., Brisse, H. J., Ribeiro, A., Mosseri, V., Rubie, H., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603820 · Cited by 96
Ozkaynak, M. F., Gilman, A. L., London, W. B., Naranjo, A. H., Diccianni, M. B., Tenney, S. C., Smith, M. A., Messer, K. S., Seeger, R. C., Reynolds, C. P., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01355 · Cited by 87
Self-citationYanik, G. A., Parisi, M. T., Naranjo, A. H., Nadel, H. R., Gelfand, M. J., Park, J. R., Ladenstein, R. L., Pöetschger, U., Boubaker, A., Valteau‐Couanet, D., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.195883 · Cited by 84
Self-citationLiang, W. H., Federico, S. M., London, W. B., Naranjo, A. H., Irwin, M. S., Volchenboum, S. L., & Cohn, S. L. (2020) · JCO Clinical Cancer Informatics · doi:10.1200/cci.20.00074 · Cited by 80
Self-citationSokol, E., Desai, A. V., Applebaum, M. A., Valteau‐Couanet, D., Park, J. R., Pearson, A. D. J., Schleiermacher, G., Irwin, M. S., Hogarty, M. D., Naranjo, A. H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03285 · Cited by 78
Self-citationAssessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies
Abbou, S. D., Shulman, D. S., DuBois, S. G., & Crompton, B. D. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27595 · Cited by 72
The challenge of defining “ultra‐high‐risk” neuroblastoma
Morgenstern, D. A., Bagatell, R., Cohn, S. L., Hogarty, M. D., Maris, J. M., Moreno, L., Park, J. R., Pearson, A. D. J., Schleiermacher, G., Valteau‐Couanet, D., et al. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27556 · Cited by 71
Self-citationMoreno, L., Guo, D., Irwin, M. S., Berthold, F., Hogarty, M. D., Kamijo, T., Morgenstern, D. A., Pasqualini, C., Ash, S., Pötschger, U., et al. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28794 · Cited by 41
Self-citationGranger, M. P., Naranjo, A. H., Bagatell, R., DuBois, S. G., McCune, J. S., Tenney, S. C., Weiss, B., Mossé, Y. P., Asgharzadeh, S., Grupp, S. A., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.03.006 · Cited by 32
Self-citation
Cited by
Advancing therapy for neuroblastoma
Qiu, B., & Matthay, K. K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00643-z · Cited by 407
Metadata
- Authors
- Irwin, M. S., Naranjo, A., Zhang, F. F., Cohn, S. L., London, W. B., Gastier-Foster, J. M., Ramirez, N. C., Pfau, R., Reshmi, S., Wagner, E., Nuchtern, J., Asgharzadeh, S., Shimada, H., Maris, J. M., Bagatell, R., Park, J. R., & Hogarty, M. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2021-10-10
- Volume
- 39
- Issue
- 29
- Pages
- 3229-3241
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3184057816
- Cited by
- 494
- References
- 43
- FWCI
- 28.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.